Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
LA JOLLA, Calif., Sept. 14, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Wednesday, September 21, 2016 at 9:30 a.m. PDT (12:30 p.m. EDT). The conference will be held from September 20-22, 2016 in Las Vegas.
A live audio webcast and replay will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
